A Phase II, Multicentre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children Aged greater than or equal to 6 Months to less than 9 Years.

Trial Profile

A Phase II, Multicentre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children Aged greater than or equal to 6 Months to less than 9 Years.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs CSL 425 (Primary) ; Influenza A virus H1N1 vaccines (Primary)
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors CSL; Seqirus
  • Most Recent Events

    • 24 May 2010 Actual end date (1 Apr 2010) added as reported by ClinicalTrials.gov.
    • 24 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Dec 2009 Results presented in a CSL media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top